Bcl 2 

 94 Products   94 Products   716 Diseases   78970 News 


12345678910111213...10711072»
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Journal, HEOR, Cost-effectiveness:  Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. (Pubmed Central) -  Apr 1, 2025   
    This study provided a solid theoretical foundation and innovative approach for the development of CDDS, utilizing molecular-scale regulation for drug co-assembly. Our analysis suggests that, from a US health care system perspective, toripalimab in combination with chemotherapy does not demonstrate a significant cost-effective advantage over nab-P chemotherapy as a first-line treatment for patients with TNBC at a WTP threshold of $100,000/QALY and has a limited impact on US health care policy and clinical practice.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Enrollment change:  Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov) -  Apr 1, 2025   
    P2,  N=106, Completed, 
    Our analysis suggests that, from a US health care system perspective, toripalimab in combination with chemotherapy does not demonstrate a significant cost-effective advantage over nab-P chemotherapy as a first-line treatment for patients with TNBC at a WTP threshold of $100,000/QALY and has a limited impact on US health care policy and clinical practice. Active, not recruiting --> Completed | N=53 --> 106
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Journal:  Prognostic impact of co-mutations in adults with IDH1/2-mutated acute myeloid leukemia. (Pubmed Central) -  Apr 1, 2025   
    Finally, hematopoietic stem cell transplantation in first complete remission significantly improved RFS (p = 0.015) and there was a trend toward improvement in OS (p = 0.282) for patients with the DNMT3A mutation but it did not benefit 2 subgroups with the IDH1/2+/NPM1+/DNMT3A- and IDH1/2+/NPM1+/FLT3-ITD- genotypes. In summary, this study provides a reference for risk stratification and treatment implications for patients with IDH1/2-mutated AML as well as for comparison with results of IDH inhibitor- or venetoclax-based combination therapy.
  • ||||||||||  paclitaxel / Generic mfg.
    Journal:  GMCL1 Controls 53BP1 Stability and Modulates Paclitaxel Sensitivity in Cancer. (Pubmed Central) -  Apr 1, 2025   
    We propose that in cancers with high GMCL1 levels, the CRL3 GMCL1 -mediated degradation of 53BP1 prevents the formation of the mitotic stopwatch complex, leading to p53 degradation and sustained proliferation. Finally, our results indicate that GMCL1 inhibition represents a novel strategy to restore taxane sensitivity in resistant cancers.
  • ||||||||||  iparomlimab (QL1604) / Qilu Pharma, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
    Enrollment open:  QIBA-CER-003: Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC (clinicaltrials.gov) -  Apr 1, 2025   
    P2,  N=35, Recruiting, 
    These findings suggest that combining FOLFIRI with IP paclitaxel warrants further investigation in Phase-I clinical trials for SRCC patients. Not yet recruiting --> Recruiting
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Inqovi (decitabine/cedazuridine) / Otsuka
    Review, Journal:  Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients. (Pubmed Central) -  Mar 31, 2025   
    The oral combination of decitabine and cedazuridine (C-DEC), which is therapeutically and pharmacologically equivalent to the intravenous (IV) formulation (IV-DEC), has expanded the therapeutic arsenal for AML, allowing for better convenience of administration...To summarize the most recent developments as up-to-date as possible, we considered, with a few exceptions, only papers published over the last three years until March 2025. Compared to IV-DEC, C-DEC provides similar therapeutic exposure and efficacy with an optional safety profile, enhanced treatment adherence, reduced treatment burden, and required healthcare facilities compared to those associated with IV-DEC, providing a precious tool to manage older and unfit AML patients.
  • ||||||||||  navitoclax (ABT 263) / AbbVie, alisertib (MLN8237) / Puma
    Journal:  Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer. (Pubmed Central) -  Mar 31, 2025   
    Furthermore, the synergistic effect of MLN8237 and ABT263 in inducing intrinsic apoptosis was primarily driven by the inhibition of the AKT-Mcl-1 and Bcl-xL survival pathways in cultured tumor cells. Together, these findings support the MLN8237-ABT263 combination as an effective treatment strategy for TNBC, promoting both immune-mediated extrinsic apoptosis and inactivation of Bcl-xL/Mcl-1-dependent intrinsic anti-apoptotic pathways.
  • ||||||||||  paclitaxel / Generic mfg., trimetazidine / Generic mfg.
    Trial completion:  Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy (clinicaltrials.gov) -  Mar 31, 2025   
    P1/2,  N=60, Completed, 
    These results suggested that the PTX-loaded Arg-CD-Bio/BM-HA-Man inclusion complex was a promising platform for efficient cancer treatment. Recruiting --> Completed
  • ||||||||||  paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Amphonal, a new polyene aldehyde from a deep-sea-derived Streptomyces amphotericinicus. (Pubmed Central) -  Mar 30, 2025   
    In the cytotoxicity evaluation, compound 2 showed significant growth inhibition against the drug-resistant human lung cancer cell line A549-Taxol with IC value of 0.44??M, which was more potent than the positive control doxorubicin. Meanwhile, 2 showed considerable cytotoxic effect towards H1975, H1299 and HEL cell lines (IC = 0.93-4.73??M) as well.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly, paclitaxel / Generic mfg., Opdivo (nivolumab) / BMS
    P2/3 data, Journal:  S2303: phase II/III trial of paclitaxel + ramucirumab  (Pubmed Central) -  Mar 29, 2025   
    P2/3
    However, further research is required to determine the best comparative regimen and the feasibility of venetoclax monotherapy in patients with CLL/SLL. NCT06203600.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, paclitaxel / Generic mfg.
    Journal:  Cetuximab and Paclitaxel Drug Response in Head and Neck Tumor Stem Cells. (Pubmed Central) -  Mar 28, 2025   
    The results of this study point to specific molecular factors that influence therapeutic responses in HNC, with an emphasis on the efficacy of drug combinations to overcome TSC resistance. The identification of these molecular mechanisms may provide guidelines for the development of more targeted and effective therapies against HNC, improving clinical management and patient prognoses.